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Abstract
Background: The World Health Organization (WHO) advises treatment of Mycobacterium ulcerans disease, also called ‘‘Buruli
ulcer’’ (BU), with a combination of the antibiotics rifampicin and streptomycin (R+S), whether followed by surgery or not. In
endemic areas, a clinical case definition is recommended. We evaluated the effectiveness of this strategy in a series of
patients with large ulcers of $10 cm in longest diameter in a rural health zone of the Democratic Republic of Congo (DRC).
Methods: A cohort of 92 patients with large ulcerated lesions suspected to be BU was enrolled between October 2006 and
September 2007 and treated according to WHO recommendations. The following microbiologic data were obtained: Ziehl-
Neelsen (ZN) stained smear, culture and PCR. Histopathology was performed on a sub-sample. Directly observed treatment
with R+S was administered daily for 12 weeks and surgery was performed after 4 weeks. Patients were followed up for two
years after treatment.
Findings: Out of 92 treated patients, 61 tested positive for M. ulcerans by PCR. PCR negative patients had better clinical
improvement than PCR positive patients after 4 weeks of antibiotics (54.8% versus 14.8%). For PCR positive patients, the
outcome after 4 weeks of antibiotic treatment was related to the ZN positivity at the start. Deterioration of the ulcers was
observed in 87.8% (36/41) of the ZN positive and in 12.2% (5/41) of the ZN negative patients. Deterioration due to
paradoxical reaction seemed unlikely. After surgery and an additional 8 weeks of antibiotics, 98.4% of PCR positive patients
and 83.3% of PCR negative patients were considered cured. The overall recurrence rate was very low (1.1%).
Interpretation: Positive predictive value of the WHO clinical case definition was low. Low relapse rate confirms the efficacy
of antibiotics. However, the need for and the best time for surgery for large Buruli ulcers requires clarification. We
recommend confirmation by ZN stain at the rural health centers, since surgical intervention without delay may be necessary
on the ZN positive cases to avoid progression of the disease. PCR negative patients were most likely not BU cases. Correct
diagnosis and specific management of these non-BU ulcers cases are urgently needed.
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Introduction
Mycobacterium ulcerans disease, commonly called ‘‘Buruli ulcer’’
(BU), is a neglected and emergent tropical disease [1,2], with
Africa being the most affected continent [3]. For many years,
management of the disease relied mainly on surgical procedures
[4,5,6]. Other treatment strategies included antibiotics alone or
followed by surgery [7,8].
A proof-of-principle study (phase-2 trial) conducted in Ghana
evaluated the efficacy of the combination of rifampicin and
streptomycin (R+S) on early BU lesions (nodules and plaques), and
found that after 4 weeks of treatment with these drugs, it was no
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longer possible to cultivate M. ulcerans from these lesions [9]. This
pilot trial led to the World Health Organization (WHO)
recommendation to treat all BU lesions with R+S, whether
followed by surgery or not [10].
WHO guidelines define three categories of treatment based on:
(1) clinical form (ulcerative or non-ulcerative), (2) lesion size
(lesions less than 5 cm and lesions of 5 cm or more in diameter),
and (3) disseminated or mixed forms. Antibiotic treatment of 8
weeks is recommended for all three categories. For lesions $5 cm,
surgery is recommended, if necessary, after at least 4 weeks of
antibiotic treatment [10]. In 2005, WHO indicated that for very
large lesions, antibiotic treatment may be administered for up to
12 weeks [11].
A case-series in Benin showed that of 224 patients treated by the
WHO strategy, 215 were successfully treated, with 47% of them
receiving antibiotics only. The size of the lesion was the major
parameter in deciding to treat by surgery: 73% of patients with
lesions of .15 cm in diameter underwent surgery, compared to
17% of patients with lesions of ,5 cm [12]. More recently,
Nienhuis et al. demonstrated that antimycobacterial treatment
alone was effective in 151 patients with early limited BU disease
[13]. The efficacy of R+S therapy on large ulcerated forms of BU,
which currently are the most common forms of BU in Africa
[14,15,16] remains insufficiently documented. In such cases the
efficacy of antibiotics could be compromised by the extent of the
necrosis [17].
The objective of the present study was to estimate the efficacy of
the standard WHO recommended regimen (R+S followed by
surgery) in patients with large ulcerated ulcers ($10 cm in longest
diameter) in a rural health zone (RHZ) of the Democratic Republic of
Congo (DRC). The data obtained allowed us to assess the positive
predictive value of the WHO clinical case definition for BU.
Materials and Methods
Study design
This is a prospective observational study that analyzes the
response of patients treated with R+S for 12 weeks and usually
followed by surgery after the first 4 weeks, a slight adaptation from
the 2005 WHO protocol [11]. Study procedures are summarized
in the flow sheet (Figure 1).
Study population
Patients clinically suspected of BU were recruited from the
RHZ of Nsona-Mpangu, Province of Lower-Congo in DRC. This
health zone has long been known to be moderately endemic for
BU [15,18]. Patients were enrolled between October 2006 and
September 2007 in 17 Health Centers and one General Reference
Hospital. Suspected cases were identified by the head nurse of the
Health Centre and later confirmed by two physicians, both co-
authors, (MK, Supervisor of the BU Control Program in the RHZ
of Nsona-Mpangu and J-BM, Chief of the RHZ of Nsona-
Mpangu). After this, the Principal Investigator (PI) (KK),
personally reviewed all cases. The final decision on classification
of cases for this study was reached by consensus of the three
physicians (KK, MK and J-BM).
For quality assurance, we conducted a post-hoc confirmation of
the clinical classification by evaluating photographs of lesions
taken at the start of treatment, after 4 weeks of antibiotic
treatment, at the end of the antibiotic treatment and at the healed
stage. A sample of these photographs was checked retrospectively
by three individuals: two other co-authors (WMM and FP) and by
an African colleague (Dr. G. Sopoh) from Benin all of whom are
experienced in the clinical diagnosis of BU.
Case definition
The clinical case definition of BU in this study was, ‘‘Ulcerative
lesions (maximum diameter $10 cm), painless or minimally painful, with
characteristic undermined edges and a yellowish-white necrotic base
surrounded by edematous skin’’. All consenting patients fitting this
definition were treated in accordance with WHO recommenda-
tions. They were assessed by the PI to determine inclusion in the
study. Biological samples were simultaneously collected and sent
to reference laboratories for case confirmation by 4 laboratory
methods: Ziehl-Neelsen (ZN) staining, culture, PCR, and
histopathology [1].
Inclusion criteria
1) Male and female, 3 to 75 years old
2) Residence in an endemic area (RHZ Nsona-Mpangu)
3) Informed consent by patient or guardian
Exclusion criteria
1) Previous treatment by rifampicin or streptomycin
2) Previous diagnosis of leprosy or tuberculosis
3) Pregnancy
4) Presence of cardiovascular, hepatic or renal disease,
detected during a complete physical examination
5) Loss to follow-up
Procedures
Size of lesions, collection of specimens. We used the
following methods to document the size of the lesions before,
during and after treatment. Size of lesion was calculated by
measuring the average diameter of the ulcer, taken as the mean of
the longest (at least 10 cm) and shortest perpendicular diameters.
Since the limit of the skin lesion was usually larger than the ulcer
edges, diameters were measured from the border between healthy
Author Summary
Buruli ulcer (BU) disease, a neglected devastating infection
caused by Mycobacterium ulcerans, has a huge impact
because of the massive necrotizing, disfiguring ulcers that
may result if not treated. Therapeutic options are surgery,
antibiotics or combinations of both. Since 2004, the World
Health Organization has recommended the use of
antibiotics (rifampicin and streptomycin) for the manage-
ment of the disease. The effectiveness of this antibiotic
treatment on advanced lesions is, however, not well
documented. We evaluated this strategy on large ulcers
clinically suspected to be BU, in a rural zone of the
Democratic Republic of Congo, and also assessed the
outcome of treatment based only on clinical diagnosis. All
patients were treated with antibiotics for 12 weeks and
surgery was performed after 4 weeks. BU was confirmed
by laboratory tests in 67% of the patients indicating that
the clinical diagnosis of ulcerated forms of BU may be
more difficult than usually reported. Although delayed
surgery seemed detrimental in some confirmed cases, it
was possible to treat 92% of patients successfully with low
recurrence rates (1.1%) by combining antibiotic treatment
with surgery in a rural zone. However, the need for and the
best time for surgery for large Buruli ulcers requires
clarification.
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skin and damaged skin. Tissue samples were taken under local or
general anesthesia at the start of treatment. Specimens from the
undermined edges were taken only of diseased tissue.
Laboratory analyses. Biopsy specimens were stored at 4uC
and transported at ambient temperature in a semi-solid transport
medium to the Institute of Tropical Medicine (ITM), Antwerp,
Belgium [19], where ZN staining, culture and PCR were carried
out as previously described [20]. Histopathologic analyses
were performed at three laboratories: Armed Forces Institute of
Pathology (AFIP), Washington DC, USA; Hospital of Chambe´ry,
France; and University of Minho, Braga, Portugal. At the time of
this study, due to logistical constraints for transport of biological
samples from this remote rural area of the DRC and
communication difficulties, the delay between enrollment and
availability of PCR results at point of care was at least 12 weeks.
Treatment regimen. All patients who satisfied the WHO
clinical case definition were treated according to WHO
recommendations [10,11]: i.e. 4 weeks of antibiotic treatment
(R+S), followed by surgery after day 28, and followed by 8 more
weeks of R+S. Rifampicin was administered orally at 10 mg/kg/
day and streptomycin by intramuscular injection at 15 mg/kg/
day. Surgical excision and skin grafting of the ulcers were carried
out according to procedures recommended by the WHO [5].
Dressings were changed daily with an aqueous solution of
chloramine-metronidazole-nitrofurandoı¨ne [6].
Treatment assessment. Ambulatory follow-up for all
patients was performed during treatment, except for those who
lived far from the Health Centre, had severe lesions, or had just
undergone surgery and were still hospitalized in the Health
Centre.
A first evaluation was carried out at the end of the 4th week of
R+S. The clinical outcome was classified as success (10 to 30%
reduction of the size of the ulcer and/or absence of new necrotic
tissue), clinical status quo (no change in the size of the lesion or
presence of necrotic tissue), or failure (increase in the size of the
lesion and presence of new necrotic tissue). The same evaluation
was carried out at the end of the 12th week of treatment, the only
difference being that success was interpreted as healed lesions.
Post-treatment assessment. For follow-up, patients were
seen in their village every 2 weeks by the head nurse, and every
month by the PI and the program supervisor. Disease recurrence
was defined as the reappearance of an ulcer or another form
(nodule, papule, plaque, edema or bone involvement) of the
disease at the original site of the lesion or elsewhere during the 12
months that followed the end of antibiotic treatment. Follow-up
after completion of treatment was at least 2 years for all patients.
Sample size considerations. Based on the assumptions that
the true efficacy rate (p) was 80% and with a desired precision of
10%, for a confidence interval of 95%, we needed a sample size of
64 patients.
Figure 1. Flow sheet showing process of patient selection and management.
doi:10.1371/journal.pntd.0000736.g001
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Data analysis. All clinical and laboratory data were entered
into a patient Case Record Form. The data were further entered
into an EPIINFO (Center for Disease Control and Prevention,
Atlanta, USA) database and analyzed by EPIINFO and SPSS
version 15.0 (Chicago, IL, USA) for Windows. Contingency tables
were analyzed by the Pearson chi-square test and Fisher exact tests
with a statistical significance-level of a= 0. 05.
Ethical aspects
The study protocol was approved by the Ethical Committees of
the Universitair Ziekenhuis Antwerpen, (Nu 6/42/197) in Belgium
and of the School of Public Health, University of Kinshasa, (Nu
ESP/CE/043) in DRC. Management of patients was free of
charge. Participation in the survey was voluntary and written
informed consent was obtained from all participants or their
guardian.
Results
Of 94 eligible patients, two were excluded: one refused
treatment and one was lost to follow-up. Overall, 92 patients
were included in this study with a mean ulcer size of 13.81 cm (SD
16.21). The male/female ratio was 0.88. Only patients with ulcers
of more than 10 cm in longest diameter were included, thus 90
patients were classified as WHO Category II and two as Category
III because of multiple lesions (Table 1).
A total of 61 (66.3%) patients were positive by PCR for M.
ulcerans (group I) and 31 were PCR negative (group II) at the start
of treatment. Table 1 presents the characteristics of group I and
group II patients at start of treatment. There was no age difference
noted between the two groups. There were significantly more
female patients in group I (60.6%) compared to group II (38.7%)
(p = 0.046). The lower limbs were significantly more frequently
affected in group II (74.1%) than in group I (52.4%) (p = 0.044).
The average diameter of the ulcer in group I was 10.07 cm
(SD = 1.95). In group II, it was 11.39 cm (SD 5.82). The difference
in initial diameter of the ulcers between groups I and II at the
beginning of treatment was not statistically significant (p = 0.320).
Of the 61 PCR positive patients (group I), 48 patients (78.7%)
had a positive ZN and 22 (36.1%) were culture positive for M.
ulcerans, whereas none (0%) of the 31 PCR negative (group II)
patients were ZN positive or culture positive (p,0.001).
Histopathologic data were available for 49 patient samples (20
PCR positive and 29 PCR negative). As shown in Table 1, 95.0%
(19/20) of the PCR positive patients had histopathologic features
compatible with BU: i.e. contiguous coagulation necrosis of the
lower dermis, subcutaneous tissue and underlying fascia; vasculitis
in the subcutaneous tissue, and presence of AFB. None of the 29
PCR negative patient samples were positive for AFB. In 25
patients (86.2%) histopathologic analysis revealed no characteristic
feature of BU and specimens from 12 patients (48.0%) showed
chronic inflammation. Five patients (20.0%) had bacterial
Table 1. Characteristics of PCR positive and PCR negative patients at start of treatment.
PCR positive patients (group I) PCR negative patients (group II) P value
n=61 n=31
Age (year) p = 0.398
,15 28 (45.9%) 10 (32.2%)
15–49 27 (44.3%) 16 (51.6%)
$50 6 (9.8%) 5 (16.1%)
Gender p = 0.046
Female 37 (60.6%) 12 (38.7%)
Male 24 (39.3%) 19 (61.2%)
Localization p= 0.168
Trunk 6 (9.8%) 4 (12.9%)
Buttock 1 (1.6%) -
Upper limb 20 (32.8%) 4 (12.9%)
Lower limb 32 (52.5%) 23 (74.2%)
Multiple 2 (3.3%) -
Ulcer size
Average diameter cm (SD) 10.07 (1.95) 11.39 (5.82) p = 0.320
Laboratory tests
Direct microscopy p,0.001
Positive ZN 48 (78.7%) 0 (0%)
Negative ZN 13 (21.3%) 31 (100%)
Culture p,0.001
Positive 22 (36.1%) 0 (0%)
Negative 39 (63.9%) 31 (100%)
Histopathologic features (49 patients) p,0.001
Compatible with BU 19/20 (95.0%) 4/29 (13.8%)
Not compatible 1/20 (5.0%) 25/29 (86.2%)
doi:10.1371/journal.pntd.0000736.t001
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suprainfections with gram-positive cocci. Four patients (16.0%)
had other dermatologic affections (impetigo, pyogranulomatous
dermatitis, chronic dermatitis, hidradenitis). Three patients had
vascular disorders and one a dermatophytosis. Only four of the 29
PCR negative patients had histopathologic changes compatible
with BU but were AFB negative.
Clinical responses in the 2 groups after 4 weeks of antibiotic
treatment are presented in Table 2. PCR negative patients had a
higher percentage of clinical improvement (54.8%) than PCR
positive patients (14.8%). This difference was statistically signifi-
cant (p,0.001). As shown in Table 3, for the 61 PCR-positive
patients, the clinical outcome at the 4th week assessment was
related to ZN and culture results at the start of treatment. Indeed,
after 4 weeks of R+S, significantly more treatment failures were
observed among the ZN positive patients, 75.0% (36/48),
compared to only 38.5% (5/13) of the ZN negative patients
(p = 0.013). Treatment successes were obtained in 6.3% (3/48) of
the ZN positive patients compared to 46.2% (6/13) of the ZN
negative patients. Similarly the outcome was more successful for
culture negative patients (8/39 or 20.5%) than for patients with
positive M. ulcerans cultures (1/22 or 4.5%). The latter difference,
however, was not significant.
All patients underwent surgical excision after the 4th week
except one PCR negative patient who refused surgery. This
patient died one month after the end of treatment due to
septicemia. After surgical excision of the lesions in the 91
remaining patients, skin grafting was performed when good
granulation tissue had formed.
Table 2 presents the clinical outcome at the end of the 12th
week of treatment. All but one patient in group I were cured
(98.4% success). The failed case developed disseminated BU with
osteomyelitis. For patients in group II, 25 patients (83.3%) were
cured; lesions of 4 (13.3%) patients deteriorated and one patient
remained unchanged. The difference in the outcome at 12 week
between group I and group II was statistically significant
(p = 0.023). In addition, there was a significant difference
(p = 0.026) in the average time of scarring of ulcers between
group I and group II patients. Indeed, PCR positive patients had a
longer average time to scarring (10.4 weeks) than PCR negative
patients (7.5 weeks). The 4 failure cases were treated with regular
dressings only and were cured after seven to 12 months.
Two recurrences were observed among the 61 patients with
positive PCR. A 7-year-old patient presented with new ulceration
at the original site five months after the ulcer had healed.
Microbiologic analyses (ZN and PCR) of biopsy specimens were
negative. After interview, it became clear that the patient’s scar
had been accidentally traumatized. The lesion completely healed
after a few days and thus, this was not a true recurrence. An 8-
year-old patient presented with an ulcer associated with osteomy-
elitis of the humerus at the original site of the lesion (right elbow)
six months after the end of R+S treatment. This patient also
showed functional limitations with contracture and substantial
decrease of mobility in the right elbow. No laboratory test was
performed at recurrence as the patient and his parents refused
surgical biopsy and any surgical prevention of disability treatment
at this time. Seven months after the recurrence, the patient
accepted surgery but despite interventions performed by plastic
surgeons, the patient was left with severe sequelae.
No disease recurrence was observed among patients with
negative PCR.
Discussion
This cohort study of large BU-like lesions in rural RDC has two
major outcomes: i) the positive predictive value of the WHO
clinical case definition (i.e. the number of true BU cases among all
the BU-like lesions studied) was low, and ii) delaying surgical
treatment to week 4 of antibiotic treatment may be detrimental for
ZN positive cases with large ulcers. The criteria for case
ascertainment used in this study to discern whom to treat for
BU were primarily clinical and epidemiological. We analyzed
clinical outcomes of the patients in our cohort into two distinct
groups according to PCR results. PCR analysis was retained
because of its high sensitivity compared to the other laboratory
tests for the diagnostic confirmation of BU [20–21]. Using a
clinical diagnosis as reference standard, Chauty et al. [12]
obtained a PCR positivity of 57.2%. Using the same reference
standard, Mensah-Quainoo et al. [22] had a PCR positivity of
72.3% and Stienstra et al. [23] had 74.8%. In our study, the PCR
positivity was 66.3% and did not substantially differ from the
above mentioned publications in which clinical diagnosis was the
only reference standard.
The fact that 33.7% (31/92) of our clinically suspected cases of
BU were PCR negative raises the question of whether or not these
ulcers were really M. ulcerans infections. Clinically suspected cases
of BU may be PCR negative if the collection of specimens is not
Table 2. Response to the antibiotic combination, rifampicin + streptomycin followed by surgery, in patients with a clinical
diagnosis of Buruli ulcer, according to initial PCR status.
PCR positive patients
(group I)
PCR negative patients
(group II) P value
Clinical outcome at 4 week assessment (before surgery) n = 61 n= 31 p,0.001
Success 9 (14.8%) 17 (54.8%)
Status quo 11 (18.0%) 2 (6.5%)
Failure 41 (67.2%) 12 (38.7%)
Clinical outcome at 12 week assessment (R&S with surgery) n = 61 n= 30 p= 0.023
Success 60 (98.4%) 25 (83.3%)
Status quo 0 1 (3.3%)
Failure 1 (1.6%) 4 (13.3%)
Average time of scarring (weeks) 10.4 7.5
Recurrences 1 0
doi:10.1371/journal.pntd.0000736.t002
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adequate. In our study, the collected specimens were inadequate
for histopathologic diagnosis of BU for 5 of 29 PCR negative
patients (biopsy specimens too superficial). It is, however, unlikely
that the PCR negative results were related to inadequate sampling
because for each patient, 2 to 5 specimens were collected and
other tests (ZN stained smears and culture) were negative for all
specimens.
Among the 29 PCR negative patients analyzed by histopathol-
ogy, 25 showed histopathologic features not compatible with BU
at start of treatment. Most specimens showed chronic inflamma-
tion and some showed bacterial infection due to gram positive
cocci. Microbiologic and histopathologic analyses indicate that the
PCR negative patients were most likely not BU cases although the
clinical aspects of the ulcerated lesions were considered compatible
with BU by three physicians who made the diagnosis in DRC
before treatment. The histopathologic examinations provided
accurate diagnoses for some of these cases (ulcers due to bacterial
infections with gram positive cocci, vascular disorders, dermato-
phytosis) [24,25,26].
Four PCR negative patients, however, showed histopathologic
features compatible with BU (extensive coagulation necrosis in
subcutis) but no AFB were seen. Their clinical status at 4 weeks
was deteriorating. Histopathologic changes of these lesions were
nonspecific [17,25,27]. In our opinion, the absence of AFB in
histologic examination and negative PCR results make the
diagnosis of BU very unlikely for most patients classified in group
II, thus we may conclude that the positive predictive value of a
clinical case definition of BU was low in this series of large
ulcerated lesions.
A post-hoc confirmation of the clinical diagnosis of a sample of
PCR negative patients, based on retrospective examination of
photographs taken before treatment, did not reveal typical BU
features.
The clinical diagnosis of ulcerated forms of BU may be more
difficult than is usually recognized, underlining the importance of
confirmation by laboratory tests [1,20]. The clinical response after
4 weeks of antibiotic treatment was significantly more successful
for PCR negative patients (54.8%) than for PCR positive patients
(14.8%). If these PCR negative ulcers were due to bacteria other
than M. ulcerans it is likely that the antibiotic treatment was efficient
against these bacteria (gram positive coccal infections).
For PCR positive patients, the clinical outcome after 4 weeks
was related to the ZN positivity at the start of antibiotic treatment.
Indeed, successful treatment after 4 weeks of antibiotic treatment
was observed in 46.2% (6/13) of the ZN negative patients and in
6.3% (3/48) of the patients who were ZN positive at the start of
treatment. Deterioration of the ulcers was observed in 87.8% (36/
41) of the ZN positive patients and in 12.2% (5/41) of the ZN
negative patients.
Increase in size of ulcer after 4 weeks, however, does not
necessarily imply treatment failure. Paradoxical worsening during
treatment was recently reported by O’Brien et al. [28]. As stated
by Johnson [29], these reactions may indeed ‘‘contribute to the
view that antibiotics are ineffective’’. According to Chauty et al.
[30], Nienhuis et al. [31] and O’Brien et al. [28], these reactions
may be characterized by an initial clinical improvement on
antibiotic treatment followed by clinical deterioration and by
symptoms such as pain and increasing local temperature.
Accordingly, histopathologic examination of excised tissue after
antibiotic treatment shows florid inflammatory reactions [28].
None of our patients whose lesions enlarged after 4 weeks of
antibiotic treatment presented an initial improvement during the
first weeks of antibiotherapy or experienced pain or increased local
temperature. Moreover, histopathologic examination of tissue
excised after 4 weeks of treatment only revealed an increase of the
chronic type of inflammatory response in some patients, as
previously described following antibiotic treatment [29]. A
significant decrease of the positivity for the laboratory tests was,
however, observed after 4 weeks of antibiotic treatment indicating
that the drugs had some effect on the bacilli (data not shown). Loss
of potency of the antibiotics was not an issue since cold chain
measures were respected and antibiotics were kept in refrigerators.
We, therefore, consider these clinical deteriorations after 4
weeks as probable failures. Although paradoxical reactions during
antibiotic treatment should be better documented in patients with
large ulcerated lesions, we believe that ZN positive patients should
be treated by surgery without delay since previous studies have
suggested an association between the ZN positivity of cutaneous
lesions and bone dissemination [32]. This concern was illustrated
by one of our PCR positive patients who was ZN positive and did
not present any clinical evidence of bone involvement at the start
of treatment but developed a recurrence with osteomyelitis and
severe deformities six months after the end of antibiotic treatment.
The need of immediate surgery for ZN positive large ulcers
remains, however, speculative and further studies are required to
determine its importance in the management of BU.
After 12 weeks of antibiotic treatment including surgery after
the 4th week, 98.4% (60/61) of the PCR positive patients and
83.3% (25/29) of the PCR negative patients were cured. The
16.7% of PCR negative patients who were not cured in our series
could have been cases of non-bacterial origin.
After a follow-up of 2 years, there was only one recurrence
among the 91 patients (1.1%). This recurrence rate falls within the
range of ,2% published by WHO [1]. Indeed, according to
Table 3. Clinical outcome of 61 PCR-positive Buruli ulcer patients after 4 weeks of antibiotic treatment, and correlation with
microbiological status at start of treatment.
Microbiological results at start of treatment
Clinical outcome at 4 week
assessment Ziehl-Neelsen staining Culture
ZN+ (%) ZN- (%) Culture+ (%) Culture- (%)
Treatment failure (n = 41) 36 (75.0) 5 (38.5) 19 (86.4) 22 (56.4)
Status quo (n = 11) 9 (18.6) 2 (15.4) 2 (9) 9 (23.0)
Success (n = 9) 3 (6.3) 6 (46.2) 1 (4.5) 8 (20.5)
TOTAL 48 (100.0%) 13(100.0%) 22(100.0%) 39(100.0%)
Status quo = no change in lesions.
doi:10.1371/journal.pntd.0000736.t003
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WHO, recurrences, reported in 16–30% of cases after surgical
treatment alone, have fallen to ,2% following the introduction of
antibiotics (R+S) [1]. Given our high cure (92.4%) and low
recurrence rates (1.1%), it seems beneficial to treat large ulcers,
whether BU confirmed or not, with antibiotics. The very low
relapse rate confirms the efficacy of antibiotics. However, the need
and the best time for surgery for large ulcers should be clarified.
Further studies are also required to define the type of antibiotic
therapy for non-BU large ulcers, and ideally should be based on
specific diagnoses.
A potential weakness of our study is lack of information on the
HIV status of our patients, but at the time of the study there was
not yet any regular HIV counseling nor antiretroviral care
available. The prevalence of HIV infection in the rural area of
Nsona Mpangu is less than 3.0% according to the ‘‘Programme
National Multisectoriel de Lutte contre le VIH/SIDA’’ [33]. Co-
infection with HIV should however be studied in DRC and
elsewhere. In Benin, a case-control study comparing HIV-1/HIV2
seroprevalence in BU patients suggests HIV seropositivity
increases the risk for BU [34]. HIV infection may also render
BU highly aggressive, especially with regard to osteomyelitis.
There is also an urgent need for studies to evaluate treatment of
HIV positive BU patients with R+S and antiretroviral drugs [35].
The strengths of this study are that: 1) the study was performed
in a remote rural BU endemic area; 2) for the first time the
antibiotic treatment of patients with large ulcerated lesions was
documented with a follow-up of at least two years; 3) all cases were
laboratory confirmed by several tests including histology.
In conclusion, our study shows that health professionals dealing
with BU may have difficulties in recognizing large ulcers due to M.
ulcerans on clinical and epidemiologic basis only, hence the
importance of microbiologic confirmation by ZN staining at rural
health centres. Furthermore, in ZN positive large ulcerated forms
of BU ($ to 10 cm in longest diameter), the efficacy of antibiotic
treatment recommended by the WHO should be better docu-
mented and the need and the best time for surgery must be
clarified. Finally, our data show that it is possible to successfully
treat 92.4% (85/92) of patients suffering from large ulcers
(whether due to M. ulcerans or not) with low recurrence rates
(1.1%) by combining an antibiotic treatment with surgery in a
rural zone. The data also highlight the need for more specific
management of non-BU ulcers.
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